The influence of a HAART regimen on the expression of HIV-associated kaposi sarcoma

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 1, 2008, Pages 111-

  Paparizos, Vassilios A ^a   Kyriakis, Kyriakos P ^a   Kourkounti, Sofia ^a   Leuow, Kirsten ^a   Daskalakis, Evangelos ^a   Katsambas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; CANCER RELAPSE; CANCER RISK; CLINICAL ARTICLE; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; RECURRENT DISEASE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; SARCOMA, KAPOSI;

EID: 52049107677     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816d9d2b     Document Type: Letter

References (3)

1. Bani-Sadr F, Fournier S, Molina JM. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS. 2003;17:1580-1581.
2. Ridolfo AL, Corbellino M, Tosca N, et al. Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma? AIDS. 2004;18: 1224-1226.
3. Sgadari C, Barrilari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8:225-232.